Escriva-de-Romani S, Cejalvo JM, Alba E, Friedmann J, et al. Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study. Lancet Oncol 2025 May 5:S1470-2045(25)00140.
PMID: 40339592